We provide targeted isolation of Akkermansia muciniphila from fecal, mucosal, and environmental samples using optimized anaerobic workflows. Our screening capabilities include adhesion capacity, immunomodulation,
and exclusion of undesired strains. This ensures that researchers obtain strains with validated biological relevance and safety profiles for subsequent studies.
To guarantee taxonomic accuracy, we perform 16S rRNA sequencing, ITS sequencing for fungal contaminants, and MALDI-TOF MS fingerprinting. For novel strain registration or genome-level analysis, our whole-genome sequencing platform offers deep characterization
of Akkermansia-specific genetic features, ensuring compliance with research and regulatory requirements.
Due to its fastidious growth and sensitivity to oxygen, Akkermansia muciniphila requires tailored stabilization solutions. We offer freeze-drying, cryopreservation, and excipient screening (trehalose, skim
milk, and other protective agents) to maintain strain viability across storage and transport. Stability testing under accelerated conditions is available to provide insights into long-term performance.
We design functional assays to evaluate Akkermansia's adhesion, mucin degradation, immunomodulatory signaling, and competitive exclusion of pathogens. Mechanistic studies include transcriptomic and metabolomic
profiling to elucidate pathways associated with host-microbe interactions. This enables researchers to identify molecular signatures and biomarkers linked to Akkermansia activity.
Our in vitro co-culture platforms integrate intestinal epithelial cells, goblet cell models, and organoid systems to mimic the gut barrier environment. These systems provide controlled settings to study Akkermansia's
effects on epithelial integrity, mucus dynamics, and microbial crosstalk. Multi-omics readouts (RNA-seq, proteomics, metabolomics) deliver comprehensive insights into host responses.
We provide assays to assess Akkermansia's resilience under stressors such as oxygen exposure, bile salts, acidic pH, and nutrient limitation. These tests are critical for predicting microbial robustness
during formulation, encapsulation, and manufacturing processes.
Creative Biolabs offers anaerobic fermentation systems tailored to Akkermansia muciniphila, optimizing media components and culture parameters to maximize biomass yield. Batch and fed-batch modes are available
to accommodate small-scale pilot studies and process optimization.
For early-stage research and proof-of-concept studies, we provide controlled lab-scale production of Akkermansia muciniphila biomass. This includes viability assessment, purity validation, and QC testing
to ensure reproducibility. Researchers receive defined microbial stocks suitable for downstream applications such as functional validation, formulation development, and in vivo studies.
Fig.1
Gram staining of A. muciniphila
